Outcomes Associated with Phosphorus Binders in Men with Non-dialysis-dependent CKD

Overview

Journal Am J Kidney Dis

Specialty Nephrology

Date 2010 Aug 24

PMID 20728255

Citations 29

Authors

Csaba P Kovesdy

Olga Kuchmak

Jun Ling Lu

Kamyar Kalantar-Zadeh

Affiliations

Soon will be listed here.

Abstract

Background: Phosphorus binders are used to treat hyperphosphatemia in maintenance dialysis patients, in whom the use of these medications has been associated with lower mortality in some observational studies. It is not clear whether similar benefits can be seen in patients with non-dialysis-dependent chronic kidney disease (CKD).

Study Design: Historical cohort.

Setting & Participants: 1,188 men with moderate and advanced non-dialysis-dependent CKD at a single medical center.

Predictor: Administration of any phosphorus binder.

Outcomes & Measurements: We examined associations of any phosphorus-binder administration with all-cause mortality and the slopes of estimated glomerular filtration rate using time-varying Cox models and mixed-effects models. Associations also were examined in intention-to-treat analyses and in 133 patient-pairs matched according to propensity scores.

Results: 344 patients were treated with a phosphorus binder; 658 patients died (mortality rate, 141 deaths/1,000 patient-years; 95% CI, 131-153) during a median follow-up of 3.1 years. Treatment with phosphorus binders was associated with significantly lower mortality (adjusted HR, 0.61; 95% CI, 0.45-0.81; P < 0.001). Results were similar when exposure was modeled in intention-to-treat analyses and examining propensity-matched patients. Phosphorus-binder use was not associated with significant changes in kidney function loss.

Limitations: Results may not apply to all patients with non-dialysis-dependent CKD.

Conclusions: Administration of phosphorus binders is associated with lower mortality in men with moderate and advanced non-dialysis-dependent CKD. Clinical trials are needed to determine the risks and benefits of phosphorus-binder use in this patient population.

Citing Articles

Risk improvement and adverse kidney outcomes in patients with chronic kidney disease: findings from KNOW-CKD.

Koh H, Kim H, Jung C, Lee Y, Park J, Yoo T J Nephrol. 2022; 36(3):767-776.

PMID: 36434262 DOI: 10.1007/s40620-022-01502-x.

Association between Serum Inorganic Phosphorus Levels and Adverse Outcomes in Chronic Kidney Disease: The Fukushima CKD Cohort Study.

Oda A, Tanaka K, Saito H, Iwasaki T, Watanabe S, Kimura H Intern Med. 2021; 61(11):1653-1662.

PMID: 34803092 PMC: 9259314. DOI: 10.2169/internalmedicine.7870-21.

The Importance of Phosphate Control in Chronic Kidney Disease.

Tsuchiya K, Akihisa T Nutrients. 2021; 13(5).

PMID: 34069053 PMC: 8156430. DOI: 10.3390/nu13051670.

High Dietary Phosphate Exacerbates and Acts Independently of Low Autophagy Activity in Pathological Cardiac Remodeling and Dysfunction.

Shi M, Shepard S, Zhou Z, Maique J, Seli O, Moe O Cells. 2021; 10(4).

PMID: 33915953 PMC: 8065663. DOI: 10.3390/cells10040777.

Effects of calcium-containing phosphate binders on cardiovascular events and mortality in predialysis CKD stage 5 patients.

Tsai P, Chung C, Chien W, Chu P PLoS One. 2020; 15(10):e0241435.

PMID: 33125428 PMC: 7598463. DOI: 10.1371/journal.pone.0241435.

References

Block G, Klassen P, Lazarus J, Ofsthun N, Lowrie E, Chertow G . Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15(8):2208-18. DOI: 10.1097/01.ASN.0000133041.27682.A2. View

PAYNE R, Little A, Williams R, Milner J . Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J. 1973; 4(5893):643-6. PMC: 1587636. DOI: 10.1136/bmj.4.5893.643. View

Maschio G, Oldrizzi L, Tessitore N, DAngelo A, Valvo E, Lupo A . Effects of dietary protein and phosphorus restriction on the progression of early renal failure. Kidney Int. 1982; 22(4):371-6. DOI: 10.1038/ki.1982.184. View

Tentori F, Blayney M, Albert J, Gillespie B, Kerr P, Bommer J . Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008; 52(3):519-30. DOI: 10.1053/j.ajkd.2008.03.020. View

Gutierrez O, Mannstadt M, Isakova T, Rauh-Hain J, Tamez H, Shah A . Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008; 359(6):584-92. PMC: 2890264. DOI: 10.1056/NEJMoa0706130. View

Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G . Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005; 112(17):2627-33. DOI: 10.1161/CIRCULATIONAHA.105.553198. View

Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L . A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2007; 73(4):391-8. DOI: 10.1038/sj.ki.5002585. View

Isakova T, Gutierrez O, Chang Y, Shah A, Tamez H, Smith K . Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol. 2008; 20(2):388-96. PMC: 2637053. DOI: 10.1681/ASN.2008060609. View

. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2 Suppl 1):S1-266. View

10.

Kestenbaum B, Sampson J, Rudser K, Patterson D, Seliger S, Young B . Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2004; 16(2):520-8. DOI: 10.1681/ASN.2004070602. View

11.

Kovesdy C, Ahmadzadeh S, Anderson J, Kalantar-Zadeh K . Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int. 2008; 73(11):1296-302. DOI: 10.1038/ki.2008.64. View

12.

Jono S, McKee M, Murry C, Shioi A, Nishizawa Y, Mori K . Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000; 87(7):E10-7. DOI: 10.1161/01.res.87.7.e10. View

13.

Kovesdy C, Trivedi B, Kalantar-Zadeh K, Anderson J . Association of low blood pressure with increased mortality in patients with moderate to severe chronic kidney disease. Nephrol Dial Transplant. 2006; 21(5):1257-62. DOI: 10.1093/ndt/gfk057. View

14.

Kovesdy C, Anderson J, Kalantar-Zadeh K . Outcomes associated with serum phosphorus level in males with non-dialysis dependent chronic kidney disease. Clin Nephrol. 2010; 73(4):268-75. DOI: 10.5414/cnp73268. View

15.

Levey A, Bosch J, Lewis J, Greene T, Rogers N, Roth D . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130(6):461-70. DOI: 10.7326/0003-4819-130-6-199903160-00002. View

16.

Dhingra R, Sullivan L, Fox C, Wang T, DAgostino Sr R, Gaziano J . Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007; 167(9):879-85. DOI: 10.1001/archinte.167.9.879. View

17.

Norris K, Greene T, Kopple J, Lea J, Lewis J, Lipkowitz M . Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease. J Am Soc Nephrol. 2006; 17(10):2928-36. PMC: 3833081. DOI: 10.1681/ASN.2005101101. View

18.

Blayney M, Pisoni R, Bragg-Gresham J, Bommer J, Piera L, Saito A . High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int. 2008; 74(5):655-63. DOI: 10.1038/ki.2008.248. View

19.

Voormolen N, Noordzij M, Grootendorst D, Beetz I, Sijpkens Y, van Manen J . High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant. 2007; 22(10):2909-16. DOI: 10.1093/ndt/gfm286. View

20.

Winkelmayer W, Levin R, Avorn J . The nephrologist's role in the management of calcium-phosphorus metabolism in patients with chronic kidney disease. Kidney Int. 2003; 63(5):1836-42. DOI: 10.1046/j.1523-1755.2003.00930.x. View